Balanced treatments for fibromyalgia

Arthritis and Rheumatism

Volumn 50, Issue 9, 2004, Pages 2725-2729

  Littlejohn, Geoffrey O ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DULOXETINE; FLUOXETINE; IMMUNOMODULATING AGENT; MILNACIPRAN; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; PARATHYROID HORMONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL FEATURE; DEPRESSION; DRUG MECHANISM; DRUG UPTAKE; EDITORIAL; FIBROMYALGIA; HUMAN; IMMUNOMODULATION; OSTEOPOROSIS; OUTCOMES RESEARCH; PAIN; PAIN THRESHOLD; PRIORITY JOURNAL; REGULATORY MECHANISM; SELF CARE; SIDE EFFECT;

BIOGENIC MONOAMINES; DEPRESSION; FIBROMYALGIA; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; PAIN THRESHOLD; THIOPHENES;

EID: 4444298734     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20486     Document Type: Editorial

References (26)

1. Smythe HA, Moldofsky H. Two contributions to understanding of the "fibrositis" syndrome. Bull Rheum Dis 1977;28:928-31.
2. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001;91:165-75.
3. Banic B, Petersen-Felix S, Andersen OK, Radanov BP, Villiger PM, Arendt-Nielsen L, et al. Evidence for spinal cord hypersensitivity in chronic pain after whiplash injury and in fibromyalgia. Pain 2004;107:7-15.
4. Littlejohn GO, Weinstein C, Helme RD. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987;14:1022-5.
5. Gibson SJ, Littlejohn GO, German MM, Helme RD, Granges G. Altered heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994;58:185-93.
6. Price DD, Greenspan JD, Dubner R. Neurons involved in the exteroceptive function of pain. Pain 2003;106:215-9.
7. Millan M. Descending control of pain. Prog Neurobiol 2002;66:355-474.
8. Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med 1996;156:1047-52.
9. Crofford LJ, Demitrack MA. Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 1996;22:267-84.
10. Martinez-Lavin M, Hermosillo AG. Autonomie nervous system dysfunction may explain the multisystem features of fibromyalgia. Semin Arthritis Rheum 2000;29:197-9.
11. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000;32:305-16.
12. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66.
13. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000;41:104-13.
14. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998;37:1279-86.
15. Zijlstra TR, Barendregt PJ, van de Laar MA. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial [abstract]. Arthritis Rheum 2002;46 Suppl 9:S105.
16. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9.
17. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;112:191-7.
18. Anderberg UM, Matteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35.
19. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9.
20. Worz R. Pain in depression-depression in pain. Pain: Clinical Updates 2003;11:1-4.
21. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, et al. Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics 1999;40:57-63.
22. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996;22:285-303.
23. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90.
24. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15.
25. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, et al, for the Duloxetine Fibromyalgia Trial Group. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84.
26. Gendreau RM, Mease PJ, Rao SR, Kranzler JD, Clauw DJ. Milnacipran: a potential new treatment of fibromyalgia [abstract]. Arthritis Rheum 2003;48 Suppl 9:S616.